Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2017

Planlagt Fastgjort Låst Flyttet Genmab
1.8k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #344

    meanwhile, the company that had to put Opdivo on partial clinical hold , has some succes with.... Opdivo 😉 https://investors.bms.com/iframes/press-releases/press-release-details/2017/CheckMate--214-Study-Evaluating-Opdivo-in-Combination-with-Yervoy-Stopped-Early-for-Demonstrating-Overall-Survival-Benefit-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #345

      BMY +5% http://www.nasdaq.com/article/bristolmyers-squibb-bmy-has-risen-to-a-new-high-on-phase-3-study-news-20170907-00940

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #346

        Thanks E L - thats why Exelixis falls 10%

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #347

          Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

          favicon

          (www.fiercebiotech.com)

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #348

            At specifik ramme de immunsuppressive T-regs virker mere smart 😉

            1 Reply Last reply
            0
            • T Offline
              T Offline
              tianc
              wrote on sidst redigeret af
              #349

              Sukkeralf -Kan jeg lokke dig til at forklare kort, hvorfor Exel falder på dette?

              1 Reply Last reply
              0
              • Legolas23L Offline
                Legolas23L Offline
                Legolas23
                wrote on sidst redigeret af
                #350

                God morn

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #351

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #352

                    God morgen. 🙂

                    1 Reply Last reply
                    0
                    • M Offline
                      M Offline
                      Mogan
                      wrote on sidst redigeret af
                      #353

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        Jedi
                        wrote on sidst redigeret af
                        #354

                        Her er en opsummering af sammenhæng mellem Exel og Opdivo/Yervoy succes i RCC https://seekingalpha.com/news/3294186-exelixis-9-percent-bristol-myers-successful-study-opdivo-yervoy-rcc?app=1&uprof=45&dr=1#email_link

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          Jedi
                          wrote on sidst redigeret af
                          #355

                          Sorry - havde ikke set at Sukkeralf allerede har svaret udførligt i Biotek chatten

                          1 Reply Last reply
                          0
                          • C Offline
                            C Offline
                            CPH
                            wrote on sidst redigeret af
                            #356

                            Fin stigning i dag, - med ab på købersiden. Der er ved at være golden cross hvor 20 dages glidende gennemsnit går op igennem 50 dages glidende gennemsnit. Til dem der følger med i det.. 🙂

                            1 Reply Last reply
                            0
                            • K Offline
                              K Offline
                              Kasper_Gaarde
                              wrote on sidst redigeret af
                              #357

                              CPH, hvilken betydning har det i forhold til det tekniske?

                              1 Reply Last reply
                              0
                              • digafarmD Offline
                                digafarmD Offline
                                digafarm
                                wrote on sidst redigeret af
                                #358

                                https://www.investing.com/equities/genmab-technical er altid god som hurtigt overblik hvis man er til det tekniske

                                1 Reply Last reply
                                0
                                • digafarmD Offline
                                  digafarmD Offline
                                  digafarm
                                  wrote on sidst redigeret af
                                  #359

                                  Buy: 9 Sell: 0 Neutral: 0
                                  Summary:
                                  STRONG BUY

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #360

                                    would be fun if we could close at 1460, just like last Friday. There is a small open gap there also.

                                    1 Reply Last reply
                                    0
                                    • Legolas23L Offline
                                      Legolas23L Offline
                                      Legolas23
                                      wrote on sidst redigeret af
                                      #361

                                      Luk i 1458

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        Jedi
                                        wrote on sidst redigeret af
                                        #362

                                        Mere medvind til Opdivo https://seekingalpha.com/news/3294374-bristol-myers-opdivo-outperforms-docetaxel-treatment-resistant-lung-cancer-patients-late?app=1&uprof=45&dr=1#email_link - i solide tumorer fungerer PD-1/PD-L1 fint

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #363

                                          Here we go: NCT03277105 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
                                          https://clinicaltrials.gov/show/NCT03277105

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger